A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.
• With evaluable clinical or imaging parameters to monitor disease activity or recurrence.
• Patients or their guardians are able to understand the study and provide written informed consent.
• Hematologic and hepatic/renal function meet the safety criteria for drug administration.
Locations
Other Locations
China
West China Hospital of Sichuan University
RECRUITING
Chengdu
Contact Information
Primary
Yi Ji, PhD
jijiyuanyuan@163.com
+862885423453
Backup
Jiangyuan Zhou, Doctor
13668491160@163.com
+8613668491160
Time Frame
Start Date: 2025-09-13
Estimated Completion Date: 2028-02-01
Participants
Target number of participants: 120
Treatments
Placebo_comparator: Direct discontinuation group
Sirolimus was gradually tapered and discontinued over a 2-month period.
Experimental: Intermittent treatment group
Sirolimus was administered using a 3-days-on/4-days-off weekly schedule for 6 months, followed by gradual tapering and discontinuation over 2 months.
Related Therapeutic Areas
Sponsors
Leads: West China Hospital